Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Apr 03, 2023 11:31am
184 Views
Post# 35376242

Biomedical Optics Spie Presentation

Biomedical Optics Spie Presentation27 June 2023 • 8:45 AM - 9:00 AM CEST

Development of a protocol for whole-lung in vivo lung perfusion assisted photodynamic therapy for the treatment of lung metastases

Authors: Khaled Ramadan (presenter), Tina Saeidi, Marcelo Cypel, Lothar Lilge
 
Abstract
 
Significance: Isolated lung metastases remain a clinical challenge with standard-of-care treatments. In Vivo Lung Perfusion, a novel technique, replaces blood with acellular perfusate to allow greater light penetration for photodynamic treatments. The purpose of this study was to develop a whole-lung personalized photodynamic protocol. Results: A porcine model was used, whereby pigs underwent a simplified lung perfusion procedure, followed by photodynamic therapy with 5-ALA or chlorin e6. Dose volume histograms demonstrated homogenous light delivery. The photodynamic threshold and therapeutic windows of 5-ALA and chlorin e6 were demonstrated. Conclusions: This study demonstrated the safety and feasibility of a whole-lung perfusion assisted photodynamic therapy protocol, with in silico dosimetry planning.
 
<< Previous
Bullboard Posts
Next >>